About Us

Vigilant Diagnostics LLC, founded in 2014, has developed patented thermal contrast technology that increases the sensitivity of Lateral Flow Assays (LFAs) by 10 to 30 times, allowing for faster and more accurate diagnostic results, with fewer false negatives and false positives.

Lateral Flow Assays have been used in clinical settings since the development of the pregnancy test in the 1980s. Today, they’re widely used in labs and clinics, and in veterinary, environmental, and field testing. They’re simple and quick to use and require only a small sample amount.

The company’s patented Thermal Contrast Amplification (TCA) technology was developed at the University of Minnesota -- scroll down for details and timeline. It is designed as a platform that can be used to process a variety of existing Lateral Flow Assays.

The promise of the advanced technology that Vigilant Diagnostics has developed is to greatly reduce the time to accurate diagnosis through increased sensitivity -- which is usually found only in laboratory tests -- and to bring that advantage to point-of-care testing, for a wide variety of applications.

Complete the form below and we will send you an email with the executive summary as an attachment.

The State of Diagnostics Today

Providers rely on centralized lab facilities to run many common diagnostics. Provider overhead is high, costs are high, workflow is inefficient, care is delayed.

Our Solution

Our patented technology provides high-sensitivity, quantified results in a fraction of the time, for a fraction of the cost. It supercharges existing ubiquitous Lateral Flow Assays (LFAs) to increase sensitivity by 10x while providing quantified results.

Competitive Landscape

We compete with higher-priced, time-consuming central lab diagnostic machines on the high-end, and less-sensitive LFA readers on the low-end.

Our Growth Strategy

As an R&D company in the broad point-of-care diagnostics market, we are continuing to identify strategic areas to apply our patented technology, and we plan to license and support key players in those areas for commercialization.

History & Milestones

  • Lorem ipsum dolor sit amet, consectetur adipisicing elit.

    2012

    Original Paper on TCA Technology Published - (100+ citations)

  • Jul 9, 2020

    2013

    First Worldwide Patent for TCA Technology Submitted

  • Jul 9, 2020

    2013

    NIH Grant for Improved Diagnosis Using Thermal Contrast LFAs

  • Jul 9, 2020

    2014

    Paper Demonstrating TCA Technology With Cryptococcus Patients – (177 citations)

  • Jul 9, 2020

    2014

    U of MN - Mayo Partnership Grant for Improving Malaria Diagnostics

  • Jul 9, 2020

    2014

    Vigilant Diagnostics LLC Founded By Drs. Bischof and Chan

  • Jul 9, 2020

    2014

    Richard Carlson Joins Company As Its First CEO

  • Jul 9, 2020

    2016

    Paper Showing 8-Fold Sensitivity Improvement With TCA Reader for Flu and Malaria – (30+ citations)

  • Jul 9, 2020

    2017

    Paper on Gold Nanoparticle Design Yielding 250-Fold Sensitivity Improvement vs. Visual LFAs – (50+ citations)

  • Jul 9, 2020

    2017

    First Worldwide Patent for TCA Technology Issued - May 2017

  • Jul 9, 2020

    2017

    Industry Leader James Sackrison Joins as Consultant

  • Jul 9, 2020

    2017

    Second Patent, For LFAs Designed Specifically for TCA Reader – Filed May 2017, Published August 2017, Allowed June 2020

  • Jul 9, 2020

    2017

    NIH Grant for Developing Handheld Thermal Contrast Reader

  • Jul 9, 2020

    2020

    Paper in Conjunction with CDC Shows TCA Technology Performs Well Within Range of ELISA Lab Standards

  • Jul 9, 2020

    2020

    James Sackrison Named CTO

  • Jul 9, 2020

    2020

    Board of Directors Expanded

  • Jul 9, 2020

    2020

    NSF Grant for Rapid Development of Two COVID-19 LFAs – May 2020

  • Jul 9, 2020

    2021

    Paper published showing LFAs will soon achieve laboratory testing performance while maintaining their advantages for rapid and large-scale point-of-care use - February 2021

  • Jul 9, 2020

    2021

    Paper published showing that TCA reading improved overall influenza sensitivity by 53% for influenza A and 33% for influenza B over visual RIDTs readings  - March 2021

  • Jul 9, 2020

    2021

    Paper published in “Applied Nano Materials” showing Vigilant’s technology achieves sensitivity overlapping with PCR (laboratory) testing for detection of the spike protein for SARS-CoV-2 (COVID) - December 2021

  • Jul 9, 2020

    2024

    Vigilant Diagnostics Announces Additional $500,000 in Funding, Bringing Its Total Equity Investment Raised Date to $2,000,000 (see "News" section of website for more information)

  • Jul 9, 2020

    2025

    Vigilant Diagnostics produces 12 advanced prototype LED-based TCA readers for evaluation and testing.

Ready to find out more?

Drop us a line today!